Research Topics
| Carla J GreenbaumSummaryAffiliation: Benaroya Research Institute Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet dataCarla J Greenbaum
Benaroya Research Institute, Seattle, Washington, USA
Diabetes 61:2066-73. 2012..The robust data on the C-peptide obtained under clinical trial conditions should be used in planning and interpretation of clinical trials...
The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetesCarla Greenbaum
Benaroya Research Institute, Diabetes Clinical Research, Seattle, Washington 98101, USA
Diabetes Care 27:1202-4. 2004- High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial--Type 1 DiabetesC J Greenbaum
Benaroya Research Institute at Virginia Mason, 1201 9th Ave, Seattle, WA 98101, USA
Diabetologia 48:68-74. 2005..Using the unique population identified by the Diabetes Prevention Trial--Type Diabetes (DPT-1), our aim was to determine if these individuals were protected from type 1 diabetes... - Preservation of beta-cell function in autoantibody-positive youth with diabetesCarla J Greenbaum
Diabetes Research Program, Benaroya Research Institute, Seattle, Washington, USA
Diabetes Care 32:1839-44. 2009..To determine the extent of beta-cell function in youth with diabetes and GAD65 and/or IA2 autoantibodies... - Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetesCarla J Greenbaum
TrialNet Publications, The Biostatistics Center, Rockville, Maryland, USA
Diabetes Care 31:1966-71. 2008..The Type 1 Diabetes TrialNet Research Group and the European C-peptide Trial (ECPT) Study Group conducted parallel randomized studies to compare the sensitivity, reproducibility, and tolerability of these procedures... - Parenteral insulin suppresses T cell proliferation to islet antigensCarla J Greenbaum
Benaroya Research Institute, Seattle, WA, USA
Pediatr Diabetes 12:150-5. 2011..Further study is needed to determine whether a therapy that results in sustained suppression of T cell proliferation could yield a measurable clinical benefit... - Metabolic tests to determine risk for type 1 diabetes in clinical trialsCarla J Greenbaum
Diabetes Program, Benaroya Research Institute, Seattle, WA 98101, USA
Diabetes Metab Res Rev 27:584-9. 2011..Evaluate the reproducibility and relationship of various metabolic tests conducted as part of the Diabetes Prevention Trial-type 1 diabetes... - Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled studyVicki Seyfert-Margolis
Immune Teolerance Network, Bethesda, Maryland, USA
Diabetes 55:2588-94. 2006..They may be useful for assessment of cellular autoimmune responses involved in type 1 diabetes... - C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001Jerry P Palmer
Department of Medicine, University of Washington, and DVA Puget Sound Health Care System, Seattle, Washington 98108, USA
Diabetes 53:250-64. 2004..The development of therapies for addressing this important unmet clinical need will be facilitated by trials that are carefully designed with beta-cell function as determined by C-peptide measurement as the primary efficacy outcome... - Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucoseCarla J Greenbaum
Benaroya Research Institute at Virginia Mason Research Center, Seattle, Washington 98101, USA
Diabetes 51:951-7. 2002..This pattern of abnormalities may be characteristic of islet dysfunction early in the development of type 1 diabetes... - Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetesLisa K Gilliam
Department of Medicine, University of Washington, 1959 N E Pacific St, Box 357710, Seattle, 98195, USA
J Autoimmun 25:244-50. 2005..We examined the relationship between diabetes autoantibodies (DAA), human leukocyte antigen (HLA), and clinical course in subjects grouped by clinical diabetes type... - Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relativesNathan E Standifer
Benaroya Research Institute at Virginia Mason, 1201 Ninth Ave, Room 260, Seattle WA, 98101, USA
Diabetes 55:3061-7. 2006..These data implicate peptides of ppIAPP, GFAP, and IGRP as CTL epitopes for a heterogenous CD8(+) T-cell response in type 1 subjects and antibody-positive relatives... - Non-invasive imaging of beta cell mass: a quantitative analysisIan R Sweet
Department of Medicine, University of Washington, Seattle, Washington 98195, USA
Diabetes Technol Ther 6:652-9. 2004..However, beta cells constitute only about 1% of pancreatic mass and are distributed throughout the pancreas within tiny islets of Langerhans that are each less than the spatial resolution of non-invasive imaging technologies... - Changes in autoreactive T cell avidity during type 1 diabetes developmentNathan E Standifer
Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
Clin Immunol 132:312-20. 2009..These data implicate the outgrowth of T cells expressing higher affinity TCR in a process of antigen-specific T cell avidity maturation during the pre-clinical stage of T1D... - Evaluation of leptin levels in subjects at risk for type 1 diabetesLisa K Gilliam
Department of Medicine, University of Washington, Seattle, WA 98195 7710, USA
J Autoimmun 26:133-7. 2006.... - Insulin resistance in type 1 diabetesCarla J Greenbaum
Diabetes Clinical Research, Benaroya Research Institute at Virginia Mason, Seattle, WA 98108, USA
Diabetes Metab Res Rev 18:192-200. 2002..Finally, one could speculate that it is possible that subsets of people with mild manifestations of the type 1 autoimmune disease process could benefit from treatments aimed at improving the insulin-resistant state... - Autoimmunity to islet proteins in children diagnosed with new-onset diabetesBarbara M Brooks-Worrell
Department of Medicine, University of Washington, Seattle, Washington 98195, USA
J Clin Endocrinol Metab 89:2222-7. 2004..Moreover, the presence of obesity or acanthosis nigracans does not reliably distinguish children with or without islet cell autoimmunity... - Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetesJohn M Lachin
The Biostatistics Center, The George Washington University, Rockville, Maryland, United States of America
PLoS ONE 6:e26471. 2011..These results provide the information needed to accurately evaluate the sample size for studies of new agents to preserve C-peptide levels in newly diagnosed type 1 diabetes... 
Use of oral glucose minimal model-derived index of insulin sensitivity in subjects with early type 1 diabetes mellitusKevin M Krudys
Department of Bioengineering, Resource Facility for Population Kinetics, University of Washington, PO Box 355061, Seattle, WA 98195, USA
Metabolism 57:445-7. 2008..Given the simplicity of the OGTT relative to the traditional methods of measuring SI, the oral glucose minimal model may be appropriate for large population studies and clinical trials...- Type 1 diabetes mellitus: primary, secondary, and tertiary preventionJennifer Bollyky
Diabetes Program, Benaroya Research Institute, Seattle, WA, USA
Mt Sinai J Med 75:385-97. 2008..In this review, we wish to convey the palpable excitement in the field. It is time to determine if we can safely change the course of T1DM... - Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trialsCarla J Greenbaum
Diabetes Clinical Research, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
Clin Immunol 104:97-104. 2002.... - ICA+ relatives with DQA1*0102/DQB1*0602 have expected 0602 sequence and DR typesCarla J Greenbaum
Benaroya Research Institute at Virginia Mason Research Center, Seattle, WA 98101, USA
J Autoimmun 18:67-70. 2002.... - Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody-positive subjects in the type 1 diabetes genetics consortium databaseDavid M Tridgell
Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Washington, USA
Diabetes Care 34:988-93. 2011..The prevalence of both antibodies decreases with longer duration of type 1 diabetes. We evaluated the interaction between age of diagnosis (onset) and duration of diabetes on the percentage of GADA- and IA-2A-positive subjects... - Type I diabetes manifested solely by 2-h oral glucose tolerance test criteriaC J Greenbaum
Department of Veterans Affairs, Puget Sound Health Care System and the Department of Medicine, University of Washington, Seattle, USA
Diabetes 50:470-6. 2001..Despite the importance of beta-cell dysfunction in the pathogenesis of type I diabetes, factors other than impaired FPIR must also contribute to postprandial glucose tolerance in these subjects... - Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetesCarla J Greenbaum
Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
Diabetes 52:1059-65. 2003 - Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulationA Plesner
Department of Medicine, University of Washington, Seattle Department of Veterans Affairs, Puget Sound Health Care System, Seattle, WA, USA
Scand J Immunol 56:522-9. 2002..Sensitized macrophages may be important to high-risk DQB1*0201/*0302-associated type 1 diabetes... - Omental roll-up: a technique for islet engraftment in a large animal modelThomas R Hefty
Division of Renal and Pancreas Transplantation, Virginia Mason Medical Center, Seattle, Washington 98101, USA
J Surg Res 161:134-8. 2010..This site allows placement of the islets in a three-dimensional (3D) matrix, with growth factors, to temporarily culture the islets in vivo while revascularization progresses... - Systematic screening of potential beta-cell imaging agentsIan R Sweet
Departments of Medicine, University of Washington, Seattle, WA 98195, USA
Biochem Biophys Res Commun 314:976-83. 2004..In vivo tests of the biodistribution of glibenclamide and fluorodithizone in rats indicated that the compounds were not specifically associated with pancreas, bearing out the predictions of the in vitro screen... - Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetesR Juneja
Department of Medicine, University of Washington, Seattle, WA 98108, USA
Metabolism 50:1008-13. 2001..We therefore conclude that screening with antibodies, mainly ICA and GAD, but not age, BMI, or clinical presentation should be used to identify type 1(1/2) diabetes... - Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family StudyC J Greenbaum
Department of Medicine, University of Washington, Seattle, USA
Diabetes 48:170-5. 1999..In addition, there are a group of ICA+ relatives with low AIRg and/or multiple antibodies who have not progressed to diabetes over the course of the study... - Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patientsB M Brooks-Worrell
Department of Medicine, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98108, USA
Diabetes 48:983-8. 1999..Some subjects demonstrate PBMC responses similar to those of "classic" type 1 diabetic patients, whereas others have PBMC responses potentially distinct from type 1 diabetic patients... - Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjectsNancy A Danke
Benaroya Research Institute at Virginia Mason, 1201 Ninth Avenue, Seattle, WA 98101, USA
J Autoimmun 25:303-11. 2005.... - Role of insulin resistance in predicting progression to type 1 diabetesPing Xu
Pediatrics Epidemiology Center, University of South Florida, Tampa, Florida 33612, USA
Diabetes Care 30:2314-20. 2007..The purpose of this study was to determine whether insulin resistance is a risk factor for the development of type 1 diabetes in autoantibody-positive first-degree relatives of diabetic family members... - GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetesHelena Reijonen
Benaroya Research Institute at Virginia Mason, Seattle, Washington 98101, USA
Diabetes 53:1987-94. 2004..1 and Valpha17-Vbeta4. Presence of these high-avidity TcRs indicates a failure to delete autoreactive T-cells that likely arise from oligoclonal expansion in response to autoantigen exposure during the progression of type 1 diabetes... - Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjectsJunbao Yang
Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
J Immunol 176:2781-9. 2006.... - Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetesMaria J Redondo
Department of Endocrinology, University Clinic of Navarra, 31008 Pamplona, Spain
J Clin Endocrinol Metab 91:1705-13. 2006..Human leukocyte antigen (HLA) DQ haplotypes have the strongest genetic association with type 1 diabetes (T1DM) risk... - Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?Desmond Schatz
Department of Pediatrics, University of Florida, Gainesville, 32610, USA
Pediatr Diabetes 5:72-9. 2004..However, preservation of C-peptide production in the prediabetic period appears to indicate non-progression to clinical disease and may serve as a new surrogate for determining response to preventative efforts... - Male sex increases the risk of autoimmunity but not type 1 diabetesJeffrey P Krischer
H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
Diabetes Care 27:1985-90. 2004..We examined both the effect of the sex of the individual screened as well as the effect of the sex of the individual's proband on diabetes risk variables tested... - Future intervention trials in type 1 diabetesTerry Wilkin
Department of Endocrinology and Metabolism, Peninsula Medical School, Plymouth, UK
Diabetes Care 27:996-7. 2004 - Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1Jay S Skyler
University of Miami, PO Box 016960 D 110, Miami, FL 33101 6960, USA
Diabetes Care 28:1068-76. 2005..This randomized, double-masked, placebo-controlled clinical trial tested whether oral insulin administration could delay or prevent type 1 diabetes in nondiabetic relatives at risk for diabetes... - Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytesMary Rieck
Translational Research Program, Benaroya Research Institute, Virginia Mason, Seattle, WA 98101, USA
J Immunol 179:4704-10. 2007..By identifying an immunologic phenotype in healthy subjects which correlates with the PTPN22 1858C/T genotype, we can now explore specific hypotheses regarding pathogenesis of diseases associated with the PTPN22 1858T variant... - Health-related quality of life of children and adolescents with type 1 or type 2 diabetes mellitus: SEARCH for Diabetes in Youth StudyMichelle J Naughton
Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest University School of Medicine, 2000 W First St, Winston Salem, NC 27104, USA
Arch Pediatr Adolesc Med 162:649-57. 2008..To examine the associations between demographic and diabetes management variables and the health-related quality of life (HRQOL) of youths with type 1 or type 2 diabetes mellitus (DM)...
Research Grants
- DQB1*0602 RELATIVES--MECHANISMS FOR DIABETES PROTECTIONCarla Greenbaum; Fiscal Year: 2001..This proposal includes collaborative agreements between the University of Washington and the Universities of Florida (Gainesville), South Florida (Tampa), and Colorado. ..